Advances in Immunotherapy of Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Dongying, Yu, Yongchao, Mei, Qingyun, Wang, Ziwei, Li, Xiaojiang, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374846/
https://www.ncbi.nlm.nih.gov/pubmed/34429612
http://dx.doi.org/10.2147/OTT.S317434
_version_ 1783740203221909504
author Liao, Dongying
Yu, Yongchao
Mei, Qingyun
Wang, Ziwei
Li, Xiaojiang
Jia, Yingjie
Kong, Fanming
author_facet Liao, Dongying
Yu, Yongchao
Mei, Qingyun
Wang, Ziwei
Li, Xiaojiang
Jia, Yingjie
Kong, Fanming
author_sort Liao, Dongying
collection PubMed
description Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.
format Online
Article
Text
id pubmed-8374846
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83748462021-08-23 Advances in Immunotherapy of Malignant Pleural Mesothelioma Liao, Dongying Yu, Yongchao Mei, Qingyun Wang, Ziwei Li, Xiaojiang Jia, Yingjie Kong, Fanming Onco Targets Ther Review Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed. Dove 2021-08-14 /pmc/articles/PMC8374846/ /pubmed/34429612 http://dx.doi.org/10.2147/OTT.S317434 Text en © 2021 Liao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liao, Dongying
Yu, Yongchao
Mei, Qingyun
Wang, Ziwei
Li, Xiaojiang
Jia, Yingjie
Kong, Fanming
Advances in Immunotherapy of Malignant Pleural Mesothelioma
title Advances in Immunotherapy of Malignant Pleural Mesothelioma
title_full Advances in Immunotherapy of Malignant Pleural Mesothelioma
title_fullStr Advances in Immunotherapy of Malignant Pleural Mesothelioma
title_full_unstemmed Advances in Immunotherapy of Malignant Pleural Mesothelioma
title_short Advances in Immunotherapy of Malignant Pleural Mesothelioma
title_sort advances in immunotherapy of malignant pleural mesothelioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374846/
https://www.ncbi.nlm.nih.gov/pubmed/34429612
http://dx.doi.org/10.2147/OTT.S317434
work_keys_str_mv AT liaodongying advancesinimmunotherapyofmalignantpleuralmesothelioma
AT yuyongchao advancesinimmunotherapyofmalignantpleuralmesothelioma
AT meiqingyun advancesinimmunotherapyofmalignantpleuralmesothelioma
AT wangziwei advancesinimmunotherapyofmalignantpleuralmesothelioma
AT lixiaojiang advancesinimmunotherapyofmalignantpleuralmesothelioma
AT jiayingjie advancesinimmunotherapyofmalignantpleuralmesothelioma
AT kongfanming advancesinimmunotherapyofmalignantpleuralmesothelioma

Ejemplares similares